BACKGROUND: Quality-of-life instruments that measure specific functional consequences of mucositis are needed to assess the efficacy of therapeutic interventions targeted against mucositis and to guide patient care. The authors undertook a prospective, multicenter, observational study to assess the validity, reliability, and feasibility of a new instrument, the Oral Mucositis Weekly Questionnaire-Head and Neck Cancer (OMWQ-HN). The OMWQ-HN is a patient-reported outcome questionnaire that measures the symptoms of mucositis, including mouth and throat soreness (MTS), and their impact on patient well-being and function. METHODS: The OMWQ-HN, along with the Functional Assessment of Cancer Therapy-Head and Neck (FACT-HN), was administered 5 times over an approximately 6-week period to patients with head and neck cancer (HNC) who were receiving radiation therapy with or without chemotherapy. Information on supportive care measures also was collected. RESULTS: Seventy-five patients were enrolled and completed 93% of scheduled assessments (100% at baseline). The OMWQ-HN demonstrated good test-retest reliability (correlation coefficient, 0.80-0.89). Cross-sectional analyses to assess validity showed that OMWQ-HN scores were different across levels of pain, with those in the worst pain category reporting the highest OMWQ-HN scores. Strong correlations were observed between OMWQ-HN and FACT-HN. Patients experienced increases in MTS, which corresponded with a steady decline in function. MTS scores were highest in the patients who were taking opioid analgesics, suggesting that mucositis pain continued despite standard pain therapy. CONCLUSIONS: The current results indicated that the OMWQ-HN is a valid, reliable, and feasible instrument for assessing the impact of mucositis on patients who are receiving radiation therapy with or without chemotherapy for HNC. Copyright (c) 2007 American Cancer Society
BACKGROUND: Quality-of-life instruments that measure specific functional consequences of mucositis are needed to assess the efficacy of therapeutic interventions targeted against mucositis and to guide patient care. The authors undertook a prospective, multicenter, observational study to assess the validity, reliability, and feasibility of a new instrument, the Oral Mucositis Weekly Questionnaire-Head and Neck Cancer (OMWQ-HN). The OMWQ-HN is a patient-reported outcome questionnaire that measures the symptoms of mucositis, including mouth and throat soreness (MTS), and their impact on patient well-being and function. METHODS: The OMWQ-HN, along with the Functional Assessment of Cancer Therapy-Head and Neck (FACT-HN), was administered 5 times over an approximately 6-week period to patients with head and neck cancer (HNC) who were receiving radiation therapy with or without chemotherapy. Information on supportive care measures also was collected. RESULTS: Seventy-five patients were enrolled and completed 93% of scheduled assessments (100% at baseline). The OMWQ-HN demonstrated good test-retest reliability (correlation coefficient, 0.80-0.89). Cross-sectional analyses to assess validity showed that OMWQ-HN scores were different across levels of pain, with those in the worst pain category reporting the highest OMWQ-HN scores. Strong correlations were observed between OMWQ-HN and FACT-HN. Patients experienced increases in MTS, which corresponded with a steady decline in function. MTS scores were highest in the patients who were taking opioid analgesics, suggesting that mucositis pain continued despite standard pain therapy. CONCLUSIONS: The current results indicated that the OMWQ-HN is a valid, reliable, and feasible instrument for assessing the impact of mucositis on patients who are receiving radiation therapy with or without chemotherapy for HNC. Copyright (c) 2007 American Cancer Society
Authors: Karis Kin Fong Cheng; Vincent Lee; Chak Ho Li; Hui Leung Yuen; Joel B Epstein Journal: Support Care Cancer Date: 2011-12-14 Impact factor: 3.603
Authors: Susan Yount; Marcy List; Hongyan Du; Kathleen Yost; Rita Bode; Bruce Brockstein; Athanassios Argiris; Everett Vokes; Ezra E W Cohen; Bruce Campbell; Veronica Valenzuela; Jacquelyn George; Robyn Egan; Jessica Chen; David Meddis; David Cella Journal: Qual Life Res Date: 2007-10-06 Impact factor: 4.147
Authors: Ivana Petrovic; Hina Panchal; Paula Demetrio De Souza Franca; Marisol Hernandez; Colleen C McCarthy; Jatin P Shah Journal: Head Neck Date: 2018-12-12 Impact factor: 3.147
Authors: J A Dean; L C Welsh; K H Wong; A Aleksic; E Dunne; M R Islam; A Patel; P Patel; I Petkar; I Phillips; J Sham; U Schick; K L Newbold; S A Bhide; K J Harrington; C M Nutting; S L Gulliford Journal: Clin Oncol (R Coll Radiol) Date: 2017-01-03 Impact factor: 4.126
Authors: Canhua Xiao; Alexandra Hanlon; Qiang Zhang; Kian Ang; David I Rosenthal; P Felix Nguyen-Tan; Harold Kim; Benjamin Movsas; Deborah Watkins Bruner Journal: Oral Oncol Date: 2012-11-17 Impact factor: 5.337
Authors: Ana P Cotrim; Masanobu Yoshikawa; Abraham N Sunshine; Changyu Zheng; Anastasia L Sowers; Angela D Thetford; John A Cook; James B Mitchell; Bruce J Baum Journal: Int J Radiat Oncol Biol Phys Date: 2011-12-22 Impact factor: 7.038
Authors: Ajay Prashad Gautam; Donald J Fernandes; Mamidipudi S Vidyasagar; Arun G Maiya; Shantling Nigudgi Journal: Support Care Cancer Date: 2012-12-08 Impact factor: 3.603
Authors: Fangyi Gu; Mark K Farrugia; William D Duncan; Yingdong Feng; Alan D Hutson; Nicolas F Schlecht; Elizabeth A Repasky; Marina P Antoch; Austin Miller; Alexis Platek; Mary E Platek; Austin J Iovoli; Anurag K Singh Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-02-25 Impact factor: 4.254
Authors: Lisette van der Molen; Maya A van Rossum; Lori M Burkhead; Ludi E Smeele; Frans J M Hilgers Journal: Eur Arch Otorhinolaryngol Date: 2008-09-30 Impact factor: 2.503
Authors: Karis K F Cheng; S F Leung; Raymond H S Liang; Josepha W M Tai; Rebecca M W Yeung; David R Thompson Journal: Support Care Cancer Date: 2008-08-02 Impact factor: 3.603